Date:- 2 October, 2015


HalioDx ‘s team is attending this fall the most prestigious scientific meetings in the field of Oncology and Immuno-Oncology:

  • ECCO/ESMO European Cancer Congress, September 25-29, 2015, Vienna, Austria
  • SITC’s 30th Anniversary Annual Meeting, November 4-8, 2015, National Harbor, Maryland, USA
  • JSI (Japanese Society for Immunology) Annual Meeting, November 18-20, 2015, Sapporo, Japan
  • ESMO Symposium on Immuno-Oncology, November 20-21, 2015, Lausanne, Switzerland

HalioDx, a novel company that designs and develops a new class of immune oncology scoring tests for cancer diagnostics, is attending this fall the most prestigious upcoming meetings in the field of Oncology and Immuno-Oncology. This participation is aimed to share with scientific and medical communities the company’s technology and to build new potential partnerships.

The biotech company will be represented, inter alia, by cofounder, Dr. Jérôme Galon, who will give a series of talks on Immunoscore®.

HalioDx provides academics, clinicians and industrials with a straight line strategy to cancer diagnostics through its unique panel of immune scoring tests, the first of which is Immunoscore®. To widen its strategic positioning in the field, HalioDx welcomes new partnerships devoted to predictive biomarker selection and validation. Overall, these partnerships are designed to strengthen the development of new companion diagnostic tests by industrials, to speed up the validation of their candidate drugs by healthcare authorities and to facilitate the implementation of combination therapies.

“The diagnostics industry will play a crucial role in the large-scale adoption of innovative immunotherapies” says Vincent Fert, CEO of HalioDx. “Our company is therefore ideally positioned to contribute to the development of this new field since the analysis of the local immune response could provide a powerful indicator of immunotherapy response potential. As our approach is totally new, it is essential for HalioDx to meet with scientific and medical communities and build high potential partnerships.”



The Immune Response to Cancer Diagnostics

By precisely measuring the immune reaction in and around the tumor, HalioDx tests allow the clinician to determine the degree of severity of the patient’s disease and predict the response to treatment, regardless of the cancer stage or the molecular class.

HalioDx designs and develops a unique range of immune scoring tests, whose first-in-class product is Immunoscore®. Considered a future diagnostic standard in Oncology, this biomarker has already demonstrated strong prognostic value in colorectal cancer.

HalioDx was founded in 2014 by the former management team of Ipsogen (leader in the molecular diagnosis of leukemia), and a pioneer in integrative immunology and oncology, Dr. Jérôme Galon.
HalioDx has an experienced team of 75 employees and compliant facilities to develop, manufacture, deliver and market in vitro diagnostic products and services in immuno-oncology.



Related Files